Peluntamig targets DLL3 and CD47, potentially enhancing immune recognition and attack on cancer cells. The SKYBRIDGE study is a phase 1/2 trial assessing peluntamig's safety and efficacy in ...

Abdul Rafeh Naqash, M.D., of the University of Oklahoma is a co-senior author of a paper in Nature Communications focusing on large cell neuroendocrine carcinoma. Abdul Rafeh Naqash, M.D., is a ...

A meta-analysis of safety and efficacy of datopotamab deruxtecan and sacituzumab govitecan for second line treatment of metastatic non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract ...

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study In this European multicenter cohort, clinical data ...

We report phase I results for obrixtamig (BI 764532), a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager, in patients with previously treated DLL3-positive small cell lung cancer (SCLC), ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited ...

Neuroendocrine carcinomas (NECs), which include small-cell lung cancer (SCLC), are a highly heterogeneous group of aggressive cancers with poor prognosis, noted Martin Wermke, MD, of TU Dresden ...

Large cell carcinoma is aggressive, requiring early detection through imaging and biopsy for optimal treatment outcomes. Treatment strategies vary by stage, including surgery, chemotherapy, radiation, ...

Neuroendocrine cancer is one of the rarest types, which begins with special hormone-making cells scattered through the body, and it was the tumor with which Irrfan Khan was diagnosed back in 2018.

Genitourinary medical oncologist Dr. Michael Morris is part of a new MSK program focused on better treatments for neuroendocrine cancers, which sometimes develop when prostate and lung cancers become ...